Create personalized user journeys with Omnichannel Marketing as a Service.
Empower your marketing operations with AI and Data.
Adopt a future-proof holistic approach to content strategy.
Leverage a suite of professional services for pharma and life sciences.
Develop and enable adaptable pharma and life sciences marketing content.
Enable format-free marketing with content management platform.
End-to-end platform for content validation and sales force readiness.
AI-powered congress engagement coordinator.
Discover our story, values, and how we're making a positive impact
Explore the heart of our organization and meet the visionary minds
Join the Viseven team and grow your career with us
The Viseven team is about respect, diversity, comfortable working conditions, and equal opportunities for everyone. We explore, evolve, and adapt – together.
We’ve had mechanization and steam power, electricity and assembly lines, and computers, plus basic automation. Each industrial revolution arrived with a confident label, but also a lengthy adjustment period.
Industry 4.0, first articulated more than a decade ago, followed the same pattern. It discussed smart factories, connected systems, real-time data, and faster decisions powered by digital technologies. Around the mid-2010s, it was presented as the next inevitable leap. And like most big ideas, it was both directionally right and quite oversold in its early framing.
A decade later, the reasonable question is: why are we still talking about it? The short answer is that Industry 4.0 never really “arrived” as a finished state. What changed over the last ten years is not the idea itself, but the surrounding conditions. The technology matured, connectivity became cheaper, data volumes exploded, and AI moved from experimental to operational.
For the pharmaceutical industry, Industry 4.0, or more specifically, Pharma 4.0, is now realistically achievable and can provide the desired resilience and operational visibility. We just have to get all of the steps clear.
Pharma 4.0 is the shift to digitally connected, data-driven pharma operations, where manufacturing, quality, and supply decisions are supported by real-time data rather than manual reconciliation. It uses technologies like AI, connected sensors/systems, analytics, and automation to monitor processes, detect deviations earlier, and keep quality “built in” by design, aligned with established pharma quality system principles.
In layman’s terms, it means using connected data, digital technologies, and structured governance to make manufacturing, quality, and supply more observable, predictable, and defensible, while maintaining compliance.
When it comes to why Pharma 4.0 even matters right now, the truth is that we can see the pharmaceutical industry striving to move toward more personalized therapies, tighter supply constraints, and higher expectations around evidence and outcomes.
Personalized medicine requires smaller batches, tighter timelines, and closer coordination across R&D, manufacturing, supply, and commercial teams. That coordination is still limited by fragmented systems, delayed data, and manual handoffs. Decisions about release, supply, or patient access are often made with partial visibility, which might work for standardized products, but breaks down when treatments are individualized and time-sensitive.
Pharma 4.0 offers to address these limits by connecting data and workflows across functions. In practical terms, it proposes an idea of operational foundation that can make personalization an actual commercial reality.
The value of Pharma 4.0 is usually discussed in manufacturing terms first. Better process control, traceability, and data-driven quality decisions are where the model originally proved itself. But those operational gains can also shape what pharmaceutical companies can do commercially.
As products become personalized, and therefore, more complex, the benefits of Pharma 4.0 extend beyond the plant into how teams plan launches, engage customers, and support access and outcomes. The following areas show where these benefits are most tangible across both operations and commercialization.
Manufacturing-wise, Pharma 4.0 can minimize uncertainty by connecting equipment, process data, and quality signals into one operational view. Technologies such as industrial IoT, advanced analytics, and in-process monitoring help detect deviations earlier, investigate faster, and make batch and supply decisions with stronger evidence. The practical outcome is fewer “surprises” in production, tighter control of variability, and more reliable supply planning, especially as medical products get more complex and batch sizes shrink.
When Pharma 4.0 is treated as only a manufacturing upgrade, its benefits stay local. The plant runs better, while the rest of the organization still operates the old way.
A true practical value shows up when those improvements become usable outside the plant. When production status, quality signals, and supply constraints are visible early and shared across teams, commercial plans can stop being built on assumptions and optimistic approximations. Launch timing, campaign phasing, and market rollouts can align with what’s actually releasable and available.
In marketing, Pharma 4.0 enables personalization that is operationally realistic because it is built on connected data and governed workflows. AI systems can analyze historical and real-time signals from CRM activity, digital engagement, and real-world evidence to predict behavior patterns and improve targeting. Generative AI and modular content operations then support faster creation of audience-specific assets, while keeping approvals and compliance checks embedded into the workflow rather than bolted on at the end.
On the sales side, Pharma 4.0 shows up as practical decision support. AI agents can surface relevant HCP context, like prior engagement history, interests, next-best actions, and others, so reps prepare better and waste less time searching across systems. More advanced setups use agentic automation for workflow steps such as follow-ups and content recommendations, while keeping governance intact, so automation doesn’t turn into compliance risk.
One of the most commercially relevant benefits is the tighter link between market demand and operational reality. AI-driven forecasting can connect sales signals with manufacturing capacity and inventory levels, reducing both shortages and overproduction. When commercial teams have more accurate visibility into availability across markets, launch planning and campaign timing become easier to defend.
More and more commercial performance is being shaped by what happens after approval, not just what was proven in clinical trials. Payers and other stakeholders want to understand how a therapy performs in routine care: adherence, persistence, and outcomes in broader patient populations. That requires evidence built from real-world data. The problem is that this data is usually scattered across claims systems, patient support programs, digital tools, and internal platforms, which makes it slow to assemble and hard to defend.
Pharma 4.0 is relevant here because it treats evidence generation and supporting services as operational processes: it connects data sources through governed workflows, so teams can build a clearer, auditable picture of use and outcomes over time. The same logic applies to “beyond-the-pill” support (apps, portals, connected packaging), where the challenge isn’t the tool itself, but running it reliably and compliantly across markets. And when traceability systems are integrated end to end, transparency becomes more of an operational fact: products can be verified, issues can be investigated faster, and stakeholders get fewer reasons to doubt what’s happening between factory and patient.
The term Pharma 4.0 was coined and formalized by the International Society for Pharmaceutical Engineering (ISPE), a nonprofit association that provides various types of training and guidance regarding pharmaceutical manufacturing, workforce development, as well as regulatory and compliance collaboration.
In 2017, ISPE introduced the Pharma 4.0 framework as an extension of existing quality system principles, outlining how companies can adopt digital technologies while keeping processes reliable, traceable, and compliant. At the base of this framework is a six-component operating model. It expands traditional quality systems with new elements and enablers that help organizations digitalize their operations without losing control.
This pillar covers both people and the tools they use. In Pharma 4.0, the workforce is expected to be more flexible, creative, and capable of making decisions with the support of digital systems. At the same time, physical and digital tools are designed to be modular, reconfigurable, and ready to support smaller, more targeted outputs.
If we apply these requirements to commercial activities, like, for instance, marketing, then this would translate into teams being supported by AI tools to personalize information for different audience segments and to respond quicker to market changes without needing to rebuild content from scratch.
Information systems are responsible for collecting, processing, and sharing data across the organization. Pharma 4.0 emphasizes full integration, meaning data should move not only up and down the hierarchy, but also across the entire value network.
In commercialization, this means marketing, medical, regulatory, and sales teams working from connected platforms. Integrated systems make it possible to track content, engagement, and approvals in one place, enabling decisions based on reliable data.
This pillar focuses on how work is structured and how decisions are made across the organization. In traditional pharmaceutical environments, processes are often built around strict hierarchies, functional silos, and long approval chains. Each department works within its own boundaries, and decisions move slowly from one level to another.
Pharma 4.0 pushes a model that is value-driven, with cross-functional teams that are organized around outcomes and not departments. These teams have access to real-time data and clear process rules, which allows them to make many operational decisions without waiting for multiple layers of management.
Culture describes the shared behaviors and unwritten rules that shape how people work together and make decisions. In practice, this looks like employees focusing on their own department’s responsibilities mainly, so decisions move upward through the organization, and employees closer to day-to-day operations have limited authority to act.
If we follow what Pharma 4.0 proposes, and as systems become more connected and data becomes available in real time, people working closest to operations should be able to make informed decisions without waiting for multiple levels of approval. Control would be defined by rules, shared data, and standards in processes.
This does require a big cultural change, because employees must be comfortable working across functions, relying on shared information, and taking responsibility for outcomes within defined boundaries. However, organizations that keep purely hierarchical decision models often struggle to adopt digital ways of working.
Digital maturity describes the gradual transformation from disjointed operations to fully integrated, predictive, and, eventually, adaptive systems. In the ISPE model, this evolution happens in defined stages, starting with basic data capture and visibility, and ending on predictive and automated responses.
The key idea is that digital transformation is not a single project or technology rollout. Organizations progress step by step, improving specific processes and gaining clearer visibility into what is happening and why. Not every company needs to reach the highest maturity levels. The right level depends on the complexity of its products, processes, and market demands, but moving up the scale can improve efficiency, transparency, and control where it matters.
Data integrity by design refers to building systems where data is accurate, complete, and trustworthy by default, rather than checking or correcting it after the fact. In the Pharma 4.0 model, organizations rely on large volumes of data to drive decisions, so the focus shifts from validating individual applications to ensuring the integrity of the data itself across the entire architecture.
This requires shared data standards, clear ownership rules, and controlled data flows. Instead of isolated databases or manual transfers, data is managed in connected platforms where its origin, changes, and usage are fully traceable, and validation focuses on the reliability of the data and the underlying platforms.
Some resources might name artificial intelligence, IoT, robotics, or cloud platforms as the “pillars of Pharma 4.0”. Technology is indeed a crucial part of transformation, and without it, the transformation to Industry 4.0 wouldn’t be possible.
However, treating technologies as pillars can be somewhat misleading. A pillar, by definition, should be stable. But technology stacks tend to change far more frequently than operating models, with tools regularly upgraded, replaced, or re-architected over time.
Digital transformation can succeed or fail because of the environment in which those tools operate. If data is fragmented, processes are unclear, or teams work in silos, introducing advanced technologies usually just “speeds up” existing problems. This is why the real foundation of Pharma 4.0 is not a specific technology, but a well-designed operating model built on connected systems, clear processes, and trustworthy data.
Technologies play an essential role, but they function as enablers rather than pillars. They reveal new capabilities, once the right structure is in place.
We are not production lines experts, but we can tell you more about implementing the Pharma 4.0 model into your commercial activities. You don’t need a full-on smart-factory-style transformation to move closer to Pharma 4.0 benefits. You can start with fixing the commercial content and engagement engine: reduce rework, connect data, shorten cycles, and make decisions based on information from the field.
This is becoming even more essential than before, as digital opinion leaders and influential clinicians gain stronger voices across both professional networks and patient communities. Their recommendations travel fast, shaping both peer perceptions and patient expectations. To stay credible in this environment, pharma communication has to be more personalized, clear, effective, and trustworthy.
In the interim, content demand keeps rising while reuse stays low. Veeva reports that only 9% of commercial content was reused in 2022, and content demand grew 37% in 2021, after a 70% increase between 2018 and 2020. These pressures make it much more difficult for teams to keep up without changing how commercial processes work.
So let us describe the practical changes that your marketing, medical, and sales teams can realistically implement today.
Begin with a single, high-friction workflow, let’s say a global-to-local email sequence, or a launch asset set for one brand. Define two or three hard metrics before making any changes: approval cycle time, number of review rounds, and content reuse rate.
This focused approach is ideal, because approval timelines are usually long. Industry benchmarks show that it takes around 21 days on average to get commercial content approved, so even small improvements will make an impact.
A practical example comes from one of our clients, a global pharmaceutical company, that chose to pilot a new content approach in one local market before scaling it globally. Instead of attempting a broad transformation, the organization launched eWizard in a single country, supported by a dedicated change management program. The pilot focused on one set of commercial tactics and clear success metrics.
Within the first quarter, the local team achieved a 50% increase in content development volume compared to the previous year as well as saved 190 days of production time and £48,000 in external costs. Because the pilot was measurable and contained, it provided clear proof of value. The company then used the results to build internal momentum and expand the approach to additional brands and markets.
Most companies already have the ingredients: CRM interaction data, content usage from CLM or content platforms, and campaign performance from email or digital channels. McKinsey notes most players have sufficient data to get started and can link it into an HCP 360 to improve prioritization, channel mix, and messaging.
You don’t need a perfectly unified database, you just need to connect what already exists into a usable view of who the HCP is, how they have been engaged, and what has actually worked. It usually starts with a simple integration between three core sources:
This is one of the most practical ways to gain speed without increasing compliance risk. With modular content, reviewers can quickly see which elements were already approved and focus only on what is new or edited, so the process becomes more targeted.
This requires a content environment that supports modular structures and integrates directly with MLR systems. For example, platforms like eWizard allow teams to create content from preapproved modules and manage the full lifecycle from creation to submission.
eWizard also includes an MLR Acceleration Engine that automatically checks materials before formal review. It can proofread content, detect inconsistencies, and flag potential compliance risks based on predefined business rules or market regulations.
And because the platform integrates with MLR systems, teams can move content directly from creation into the approval workflow without manually exporting and reuploading files.
AI right now has the potential to start delivering real personalization at scale. When an AI agent is embedded into a governed content environment, it’s trained on brand rules, approved claims, tone of voice, and compliance constraints, it can safely produce many variations of a message. Combined with modular content, CRM data, and a connected content experience platform, this makes it possible to generate dozens of tailored versions of a single asset for different audiences, channels, or use cases.
This means:
The structure underneath remains the same: approved modules, connected customer data, and defined rules. AI simply accelerates the adaptation layer.
What’s crucial to note is that human input remains unwaveringly essential here. New campaign ideas, strategic angles, and creative concepts still depend on people. AI helps scale and adapt those ideas, but it does not replace the strategic thinking behind them.
Pharma 4.0 did not arrive as a single breakthrough moment. Like the industrial revolutions before it, it is unfolding gradually as the surrounding technologies mature and the industry learns how to apply them responsibly. The difference today is that many of the capabilities once discussed as future concepts are becoming practical, accessible, and increasingly expected.
The reason Pharma 4.0 remains relevant is simple: the pressures it was meant to address have only intensified. Personalized therapies, tighter supply conditions, more demanding evidence requirements, and stronger digital voices in the healthcare ecosystem all require faster, clearer, and more trustworthy decisions across the entire value chain.
Do not view Pharma 4.0 as reaching some kind of “end state.” Instead, make steady, measurable improvements that connect data, processes, and teams into a more reliable operating model.
We provide the digital platforms, AI tools, and change management expertise that help teams build modular content, accelerate approvals, and personalize engagement without disrupting what already works. Tell us about your current challenges or goals, and we’ll define a practical path forward.
Pharma 4.0 is built on an operating model that includes adaptive resources, integrated information systems, agile processes, a data-driven culture, progressive digital maturity, and data integrity by design. These elements ensure that digital transformation improves reliability rather than introducing new risks.
Technologies change quickly, while operating models need to remain stable. AI, IoT, and other tools enable new capabilities, but without connected systems, clear processes, and trustworthy data, they tend to amplify existing inefficiencies instead of solving them.
A practical approach is to focus on one high-friction workflow, define clear success metrics, and improve it step by step. This can include connecting existing data sources, introducing modular content, redesigning approval processes, and using AI to scale personalization within governed frameworks.
Because improvements stay trapped within functions. Manufacturing becomes more efficient, but commercial teams still plan based on outdated assumptions. Without a shared “digital thread” that connects production, quality, and engagement data, operational gains don’t translate into better launches or customer experiences.
